Creatine: Effects & Evidence — what’s supported and what isn’t

Creatine: Effects & Evidence — what’s supported and what isn’t

TLDR: Creatine is considered by many people to be a well-working supplement for strength and muscle building, supported by meta-analyses (including, among others, those on strength gains, repeated sprints, and specific populations). For kidney safety, cognition, and multiple performance aspects there are also reviews — but not every application is backed with the same strength of evidence. As a baseline, the big lifestyle levers remain: training, nutrition, and sleep.

Effects depend on training and energy balance — why lifestyle matters first

Creatine can support performance in training situations, but the main driver of muscle growth is still the training stimulus plus an appropriate energy and protein framework. If sleep, recovery, and nutrition aren’t in place, any added benefits from creatine are often harder to measure, because the limiting factor then isn’t the muscle’s energy buffer.

Specifically, the typical training effect appears most strongly where the muscle uses rapid energy re-supply: activities with short, intense bouts (e.g., sprints, intense sets). Creatine can increase the storage form in muscle; therefore, with appropriate stressors, it plausibly supports more energetic recovery of phosphates. (Mechanistic overview of phosphocreatine recovery in humans: Singh et al., 2025, PMID 40189235). Practically, that means: if you don’t implement these types of efforts regularly, progressively, and with adequate recovery, the real-world advantage stays limited.

Energy balance plays a hard role too: building muscle requires an overall training stimulus and a diet that provides enough raw materials and energy. Even if creatine improves repetitions or performance in intense sequences in the short term, it won’t automatically translate into more muscle mass if your weekly calorie balance is too restrictive or protein intake stays too low. That’s why it makes sense to introduce creatine into an already functional training-and-nutrition routine — or at least evaluate in parallel whether training, sleep, and nutrient distribution are truly on target.

Timing can also influence perception: the effect isn’t like an “acute energy drink” for every situation, but an adaptation over time in muscle creatine stores (indirectly supported by the mechanistic and clinical study landscape, e.g., strength/performance reviews: Zhang et al., 2025, PMID 41328071; Glaister et al., 2022, PMID 36041731). If you optimize your routine consistently, the probability of perceiving creatine as a clear additional benefit is higher.

Evidence hierarchy: from RCTs to systematic reviews — what does “high evidence” mean?

“High evidence” for supplements doesn’t mean there are never counterexamples. Instead, it means the research question has been studied across many trials with meaningful endpoints and can be systematically combined. For creatine, the most robust conclusions are typically found where systematic reviews and meta-analyses bundle many RCTs: e.g., strength and multiple performance parameters. For other topics (e.g., cognition or biomarkers), conclusions depend more on how consistent endpoints and study populations are.

Meta-analyses are especially useful because they reduce variability between individual studies and can reveal a common direction of effect. For strength and muscle strength gains, one meta-analysis reports overall positive effects of creatine, with effect sizes varying by study and endpoint (Zhang et al., 2025, PMID 41328071). For repeated sprints, a systematic review also summarizes improvements after short-term supplementation (Glaister et al., 2022, PMID 36041731). And for specific populations, reviews place additional target outcomes in context, for example for postmenopausal women with respect to lean mass, strength, and bone-density relevant measures (Naddafha et al., 2026, PMID 42141930).

Animal studies can make mechanisms plausible, but they don’t replace evidence about benefits in humans. Therefore, mechanistic arguments below are used for plausibility, not as proof of clinical endpoints. The key point is: the “softer” the endpoint and the more heterogeneous the study designs, the more cautious you should be when claiming an effect universally. For cognition, for example, a systematic review on memory in healthy people assesses RCTs and arrives at a differentiated view rather than a universal “always effective” message (Prokopidis et al., 2023, PMID 35984306). This is a common pattern you’ll find with other supplement “promises.”

If you want to go deeper into what a meta-analysis can really tell you, this context helps too: Metaanalysen: Wirkung & Studienlage—Was ist wirklich belegt?.

In short: for creatine, the evidence for strength/performance is the most robust, while other areas have been studied but often come with less consistent endpoints or smaller/more heterogeneous datasets.

Strength, muscle mass, and function: what meta-analyses report for creatine

In meta-analyses, creatine is associated on average with measurable improvements in muscle strength and various functional performance measures. How large the effect is varies by population, study duration, and which strength or function endpoints were used — but the direction in the pooled data is predominantly positive (Zhang et al., 2025, PMID 41328071).

For strength gains, Zhang et al. (2025, PMID 41328071) report a meta-analysis and systematic review connecting creatine with greater strength improvements overall than controls. The review is important because it summarizes many RCTs, increasing the likelihood that observed effects aren’t just random variation from single studies. At the same time, the exact effect size can vary depending on measurement methods (e.g., 1RM, isometric strength, dynamic tests) and training protocols.

For repeated sprints (a fit-for-sport category across teams and interval demands), the evidence in a systematic review and meta-analysis shows an advantage after short-term supplementation (Glaister et al., 2022, PMID 36041731). This aligns mechanistically with the idea that creatine supports rapid energy re-supply across multiple loading blocks. But: “short-term” in study contexts doesn’t automatically mean it improves performance for every activity indefinitely — it mainly describes the period during which the RCTs measured outcomes.

For specific groups, there are also summaries. Naddafha et al. (2026, PMID 42141930) examine creatine in a meta-analysis for postmenopausal women and derive effects on, among other outcomes, lean mass, strength, and bone-health relevant measures within the constraints of the included study designs. This is valuable because many “general” statements don’t transfer cleanly to every age and hormonal context.

Expectation management: even if creatine works on average in meta-analyses, that doesn’t automatically mean “guaranteed for you” or “without a training stimulus.” A sensible approach is: train regularly, don’t neglect protein and total energy, and evaluate creatine as an addition — not a replacement.

Mechanism in humans: phosphocreatine recovery and resilience

The practical usefulness of creatine can be explained at least partially through physiology: creatine affects phosphocreatine availability in muscle, which relates to recovery dynamics after exertion. A systematic review of (31)P-MRS findings summarizes how phosphocreatine recovery kinetics appear in health and disease (Singh et al., 2025, PMID 40189235). This supports plausibility, but it doesn’t replace a direct “X% more strength” translation for every scenario.

Why is (31)P-MRS relevant? This method allows specific phosphate compounds in muscle to be measured indirectly. Singh et al. (2025, PMID 40189235) pools findings on phosphocreatine recovery kinetics and highlights that the dynamics are measurable and vary by condition/setting. The plausible chain for creatine is: if “storage” capacity (or phosphocreatine pool size) is more available, regeneration after intense training phases under matching conditions may proceed faster or more efficiently — which then can show up in training as, for example, improved repeat performance or less fatigue.

Important for context: mechanistic endpoints are not automatically identical to performance or muscle-building endpoints. Improvements in recovery kinetics don’t necessarily mean you’ll see a proportional strength increase in every sport or training program. Also, measurement methods, training types, and starting levels differ between studies. That’s why mechanism studies are strongest for plausibility, but limited for exact predictions of “how many percent more strength.”

If you use creatine as a tool, the mechanistic expectation should be clean and realistic: the effect is most likely to be visible where repeated intense bouts occur and where training is structured progressively. If, instead, you mostly perform low-intensity or long, uniform efforts, the “energy phosphate” axis is less obviously the limiting factor.

Safety and risks: kidney, myocarditis, and fitness-adjacent endpoints

For kidney function, there is a systematic overview and meta-analysis indicating that in the studies included there were no relevant worsening effects attributable to creatine — though with clear limits related to study design and follow-up duration (Naeini et al., 2025, PMID 41199218). For viral myopericarditis, there are meta-data on sodium creatine phosphate as part of a specific therapeutic context, but that cannot be directly mapped onto fitness supplementation (Wang et al., 2025, PMID 39854433). For markers of muscle-related damage, reviews show a differentiated picture depending on which markers were measured (Northeast et al., 2021, PMID 33631721).

What’s supported for kidneys — and what isn’t

Naeini et al. (2025, PMID 41199218) assessed creatine’s effect on kidney function in a systematic review and meta-analysis. The core message is reassuring: across the included studies, creatine was not associated with relevant worsening. At the same time, it’s important not to overstate this: “not associated” is not a guarantee for every individual, and it doesn’t cover unlimited long-term high-dose use in every situation. The evidence is typically limited by study length, baseline risk, and endpoint choices. Therefore: if you have known kidney disease, you need medical evaluation rather than relying on “the review says it’s safe.”

Myocarditis: don’t mix categories

Wang et al. (2025, PMID 39854433) addresses viral myocarditis and evaluates creatine phosphate (sodium creatine phosphate) as a therapeutic intervention in a medical setting. That doesn’t automatically mean that “creatine supplements” in the sense of Creatine Monohydrate for fitness problems are safe or effective. The data refer to a clear disease context and a specific form/treatment pathway.

Training-adjacent markers of muscle stress

Northeast et al. (2021, PMID 33631721) summarizes studies on markers of exercise-induced muscle damage. The core message is: there are hints that can help with interpretation, but effects depend heavily on which markers were measured and how the intervention was conducted. This matters because many internet discussions about “muscle soreness markers” imply a single universal biological response. Reviews show instead that different endpoints can respond differently.

Practical safety logic (without unproven promises)

• If you’re prone to kidney problems or have known kidney disease: discuss with a clinician first (reason: evidence is reassuring, but not fully robust for every at-risk subgroup; Naeini et al., 2025, PMID 41199218).
• If you receive medical therapies for heart conditions: don’t add Creatin/creatine phosphate on your own and don’t derive actions from reviews (Wang et al., 2025, PMID 39854433 is a special framework).
• If you observe markers or symptoms: don’t use creatine as a “test product” without a cleanly planned training-and-nutrition framework; biomarker data are heterogeneous (Northeast et al., 2021, PMID 33631721).

Cognition and memory: what reviews found in healthy people

Creatine has been studied for cognition and memory in healthy individuals, but the review evidence isn’t consistent enough to support a simple “guaranteed better performance” claim. A systematic review of memory in healthy people evaluates RCTs and reaches a differentiated conclusion (Prokopidis et al., 2023, PMID 35984306).

What does “differentiated” mean in practice? The key point is: cognitive effects appear to depend more on factors like participants’ baseline level, the cognitive test batteries used, and study duration. This makes it harder to transfer results between studies. Prokopidis et al. (2023, PMID 35984306) integrates RCTs and shows that not every study finds a clear benefit, and that across the overall view results don’t always point in a single direction of “memory always improves.”

That matches the broader reality: cognition isn’t a one-dimensional target. Memory, attention, processing speed, and working memory may respond differently, and tests are often not directly comparable. So creatine for cognition looks more like a “potentially relevant tool” than a safe, reliable intervention.

You should also note that “healthy individuals” doesn’t automatically cover every imaginable real-life scenario. For example, if you are severely sleep-deprived, under chronic high stress, or living in an energy deficit, the limiting factors are often not primarily muscle energy but the whole system (sleep/stress/nutrition). Because lifestyle levers often “pull harder” than supplements in practice, it’s methodologically sensible to optimize those first before prioritizing cognition as a supplement goal.

If you want to learn more about zeitgebers, sleep structure, or circadian effects as cognition levers, this context may help: Circadianer Rhythmus: Wirkung & Studienlage (was belegt ist).

In short: for cognition, creatine isn’t “out,” but current data doesn’t allow a clear success guarantee. If you still want to test it, do so as an add-on to sleep and stress management, with realistic expectations and appropriate repeated testing.

Evidence by topic: which endpoints are well studied?

Not all creatine questions are equally covered by clinical data. Below you’ll find a simplified evidence matrix (based only on the reviews/meta-analyses present here) so you can quickly classify where data density is high and where it’s limited.

What you can take from this

• Strength and performance are the areas where creatine is supported most consistently in systematic reviews/meta-analyses (e.g., Zhang et al., 2025, PMID 41328071; Glaister et al., 2022, PMID 36041731).
• Lifestyle first: Creatine is an additional lever, but muscle building primarily follows the training stimulus, protein intake framework, and recovery.
• Mechanistically plausible, but not “translatable into numbers”: phosphocreatine recovery is a strong plausibility argument, but it doesn’t replace scenario-specific strength predictions (Singh et al., 2025, PMID 40189235).
• Safety appears reassuring overall for the kidney in the studied settings, but long-term/high-risk subgroups are methodologically less well covered (Naeini et al., 2025, PMID 41199218).
• Cognition is less clear: In healthy people there are indications, but the review landscape doesn’t currently support a robust “always better” conclusion (Prokopidis et al., 2023, PMID 35984306).

If you want, the next step could be a criteria-based test checklist (training days, measurement points, expected changes, and stop rules) tailored to your starting situation — without doping or hype language, purely aligned with the endpoints typically covered in the reviews.